AtriCure, Inc. Form 8-K December 16, 2011

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) of the

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 16, 2011

ATRICURE, INC.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction

000-51470 (Commission

34-1940305 (IRS Employer

of incorporation)

File Number)

Identification No.)


Edgar Filing: AtriCure, Inc. - Form 8-K

6217 Centre Park Drive

West Chester, OH 45069 (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (513) 755-4100

Not Applicable

(Former name or former address, if changed since last report)



- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On December 16, 2011, AtriCure, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved AtriCure s Synergy Ablation System for the treatment of atrial fibrillation. A copy of the press release is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

No. Description

99.1 Press Release dated December 16, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATRICURE, INC.

Dated: December 16, 2011 By: /s/ Julie A. Piton

Julie A. Piton

Vice President, Finance and Administration and

Chief Financial Officer